b'Bench-to-BedsideFRIDAY, NOVEMBER 11 (8:00-17:10)B2B URO-ONCOLOGY: GU CANCERS TRIAD MEETINGPresenting Sponsor .from 35,000 (CAN $50,673)Contributing Sponsor from 15,000(CAN$21,636)The B2B Uro-Oncology: GU Cancers Triad Meeting,Scientific Programme Committeeheld in conjunction with the 42 ndCongress of the SIU,Peter Black, Canada (Chair)offers an ideal approach to review current clinicalSimon Tanguay, Canadaresearch advancements and their applications inAlexandra Masson-Lecomte, Franceuro-oncology. This meeting will include a high-profileDerya Tilki, Germany international faculty of experts in various disciplines, providing the opportunity to foster collaborative discussions across specialties. Preliminary Programme:In this full-day session, held at the Palais des congrs8:00-8:05 de Montral, our expert faculty from around the worldWelcome and Introductionswill provide updates on the management of the three most prevalent urological cancers (prostate, bladder,8:05-10:50 and kidney cancers) by emphasizing evolving trendsBladder Cancer in the early detection of disease, recent results ofModerator: Alexandra Masson-Lecomte clinical trials, new therapies, biomarkers, and novel technologies and treatment strategies, including new10:50-12:50 surgical techniques. The programme will focus on providing insights and sharing knowledge on bestProstate Cancer practices, aimed at guiding treatment decisions, andModerator: Derya Tilki ultimately improving patient outcomes .14:00-16:05 Kidney CancerModerator: Simon Tanguay 16:05-17:05 Five Practice-Changing Advances on the Horizon:Bladder, Prostate, and Kidney Cancer Moderators: Peter Black & Simon Tanguay 17:05-17:10 Concluding RemarksExecutive Summary and Proposal availableupon requestNOVEMBER 913, 2022MONTREAL 23'